You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

495 Results
Guidelines and Advice
Status: Current
Updated
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ivosidenib,
azaCITIDine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Guidelines and Advice
Status: Current
ID: GL END 4-19
Updated
Nov 2025
Drug
Other Name(s): Rybrevant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Nov 2025
Guidelines and Advice
Status: Current
ID: GL END 9-10
Version: 2
Aug 2022
Guidelines and Advice
Status: Current
ID: GL END 5-7
Version: 3
Nov 2021
Guidelines and Advice
Status: Current
ID: 5-11
Version: 2
Jan 2022
Drug
Other Name(s): Alecensaro®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
alectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025

Pages